NASDAQ:AMED - Nasdaq - US0234361089 - Common Stock - Currency: USD
NASDAQ:AMED (4/28/2025, 3:59:03 PM)
94.785
+0.28 (+0.3%)
The current stock price of AMED is 94.785 USD. In the past month the price increased by 1.72%. In the past year, price increased by 2.95%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 12.28 | 91.00B | ||
CVS | CVS HEALTH CORP | 12 | 82.07B | ||
DGX | QUEST DIAGNOSTICS INC | 19.23 | 19.73B | ||
LH | LABCORP HOLDINGS INC | 15.82 | 19.28B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 13.54 | 14.70B | ||
DVA | DAVITA INC | 14.8 | 11.25B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 112.07 | 10.79B | ||
CHE | CHEMED CORP | 24 | 8.27B | ||
HIMS | HIMS & HERS HEALTH INC | 52.98 | 6.36B | ||
GH | GUARDANT HEALTH INC | N/A | 5.91B | ||
CRVL | CORVEL CORP | 26.3 | 5.65B | ||
OPCH | OPTION CARE HEALTH INC | 27.05 | 5.42B |
Amedisys, Inc. engages in the provision of healthcare services. The company is headquartered in Baton Rouge, Louisiana and currently employs 19,000 full-time employees. The company provides in-home healthcare and related services to the chronic, co-morbid and aging American population. Its segments include home health, hospice and high acuity care. Its home health segment delivers a range of services in the homes of individuals who may be recovering from an illness, injury or surgery. Its nurses administer medications, care for wounds, monitor vital signs and provide a range of other nursing services. Its hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. Its high acuity care segment delivers the essential elements of inpatient hospital, palliative and skilled nursing facility care to patients in their homes. The company owns and operates 347 Medicare-certified home health care centers, 164 Medicare-certified hospice care centers and eight admitting high acuity care joint ventures in 38 states within the United States and the District of Columbia.
AMEDISYS INC
3854 American Way, Suite A
Baton Rouge LOUISIANA 70816 US
CEO: Paul B. Kusserow
Employees: 19000
Company Website: https://www.amedisys.com/
Investor Relations: http://investors.amedisys.com/
Phone: 12252922031
The current stock price of AMED is 94.785 USD. The price increased by 0.3% in the last trading session.
The exchange symbol of AMEDISYS INC is AMED and it is listed on the Nasdaq exchange.
AMED stock is listed on the Nasdaq exchange.
17 analysts have analysed AMED and the average price target is 98.09 USD. This implies a price increase of 3.49% is expected in the next year compared to the current price of 94.785. Check the AMEDISYS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AMEDISYS INC (AMED) has a market capitalization of 3.11B USD. This makes AMED a Mid Cap stock.
AMEDISYS INC (AMED) currently has 19000 employees.
AMEDISYS INC (AMED) has a support level at 92.55 and a resistance level at 95.49. Check the full technical report for a detailed analysis of AMED support and resistance levels.
The Revenue of AMEDISYS INC (AMED) is expected to grow by 4.34% in the next year. Check the estimates tab for more information on the AMED EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AMED does not pay a dividend.
AMEDISYS INC (AMED) will report earnings on 2025-07-22, after the market close.
The PE ratio for AMEDISYS INC (AMED) is 20.92. This is based on the reported non-GAAP earnings per share of 4.53 and the current share price of 94.785 USD. Check the full fundamental report for a full analysis of the valuation metrics for AMED.
The outstanding short interest for AMEDISYS INC (AMED) is 7.35% of its float. Check the ownership tab for more information on the AMED short interest.
ChartMill assigns a technical rating of 6 / 10 to AMED. When comparing the yearly performance of all stocks, AMED is one of the better performing stocks in the market, outperforming 72.45% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to AMED. While AMED belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months AMED reported a non-GAAP Earnings per Share(EPS) of 4.53. The EPS increased by 4.86% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3.79% | ||
ROA | 4.11% | ||
ROE | 7.49% | ||
Debt/Equity | 0.28 |
ChartMill assigns a Buy % Consensus number of 54% to AMED. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of 11.14% and a revenue growth 4.34% for AMED